- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05631509
Genetic Study of Obstructive Azoospermia
May 7, 2024 updated by: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
In 1% of men with infertility, obstructive azoospermia (OA) may occur in congenital absence of the vas (CAVD) or idiopathic obstructive azoospermia .
Many studies have shown that the pathogenic genes of OA are CFTR and ADGRG2 genes, and the inheritance mode is autosomal recessive.
Although the conventional assisted reproductive technology(PESA/TESA) can help these patients have children, male patients who carry mutations of the disease-causing genes (CFTR and ADGRG2) will also pass on their mutations to the next generation, which will increase the risk of male offspring infertility.
Therefore, genetic detection of CFTR and ADGRG2 genes is very necessary for CAVD patients before assisted reproduction.
Genetic diagnosis plays a key role in preventing the disease to the offspring.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ping Yuan, PhD
- Phone Number: 86-20-81332230
- Email: kekeyp1983@163.com
Study Contact Backup
- Name: Liushan Ou
- Email: sysyxllwyh@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- 107 Yan Jiang Xi Road
-
Contact:
- Lingyan Zheng
- Phone Number: 86-20-81332230
- Email: lyzheng6@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
This is a non-interventional multicenter study.
The cases were mainly male outpatients from the Reproductive Center of our Hospital, Shenzhen Hospital of the University of Hong Kong and Shenzhen Hospital of Traditional Chinese Medicine.
A total of 300 cases were planned to be enrolled.
Through inclusion criteria and exclusion criteria, appropriate patients were selected for genetic testing, including sequence of known pathogenic genes (CFTR and ADGRG2) and whole- exome sequence.
If patients were found to carry mutations in CFTR, ADGRG2 or other genes, verification of family members' blood samples was required to determine the pathogenicity of mutations.
Description
Inclusion Criteria:
- No sperm was found after centrifugation for 15min for two or more semen tests, and the interval between two tests was at least 2 weeks.
- Blood FSH is normal;
- Hematostatin b is normal;
- Chromosome karyotype is normal or polymorphic;
- Y chromosome microdeletion did not show the deletion:(main locus);
- Biochemical fructose of seminal plasma : less than the normal value;
- PH of semen <7.2;
- Transscrotal or transrectal ultrasound: normal testicular size(as measured by B ultrasound), presence or dysplasia of vas deferens and epididymis;
Exclusion Criteria:
- B ultrasound of urinary system suggested abnormal development;
- Transscrotal or Transrectal ultrasound indicated absence of vas deferens or epididymis or seminal vesicle;
- Physical examination showed the following abnormalities: cryptorchidism, tenderness of testis and epididymis;
- The following medical history: genitourinary tract trauma or surgical history; orchitis; epididymitis; Seminal vesicle disease; mumps;
- Laboratory examination: red and white blood cell elevation of semen routine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mutation rate
Time Frame: through study completion, an average of 3 year
|
the mutation rate of CFTR and ADGRG2
|
through study completion, an average of 3 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2021
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
November 15, 2022
First Submitted That Met QC Criteria
November 20, 2022
First Posted (Actual)
November 30, 2022
Study Record Updates
Last Update Posted (Actual)
May 8, 2024
Last Update Submitted That Met QC Criteria
May 7, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYSEC-KY-KS-2021-116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.